[The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia]

Zhonghua Xue Ye Xue Za Zhi. 2017 Jan 14;38(1):28-32. doi: 10.3760/cma.j.issn.0253-2727.2017.01.006.
[Article in Chinese]

Abstract

Objective: To investigate the clinical manifestation, cytogenetics, gene mutations and prognostic factors of chronic neutrophilic leukemia (CNL) . Methods: 16 CNL cases, according to WHO (2016) -definition, were reviewed retrospectively. Identifications of the CSF3R, ASXL1, SETBP1, CALR and MPL mutations were performed by direct sequencing. JAK2 V617F mutation was detected by AS-PCR. Results: Of the 16 CNL patients, the median age was 64 (43-80) years with a male predominance of 75% (12/16) . The median hemoglobin was 114 (81-154) g/L, with median WBC of 41.20 (26.05-167.70) (10(9)/L and median PLT of 238 (91-394) ×10(9)/L.The median level of marrow fibrosis (MF) was 1 (0-3) degree. There was no other cytogenetic abnormalities except t (1;7) (p32;q11) , +21 and 14ps+ for each. All the 16 CNL patients harbored CSF3R T618I mutation. ASXL1 mutations were identified in 81% (13/16) , while SETBP1 mutations were confirmed in 63% (10/16) . The CALR K385fs*47 mutation was found. There was no mutation in JAK2 V617F or MPL in the above 16 patients. The median overall survival (OS) of patients presented with WBC≥50×10(9)/L at diagnosis (11 months) was significantly shorter than of WBC<50×10(9)/L (39 months, P=0.005) . Conclusion: CSF3R T618I mutation was specific for CNL. The median OS of CNL patients was 24 months, and WBC≥50×10(9)/L at diagnosis was an unfavorable prognostic factor.

目的:探讨慢性中性粒细胞白血病(CNL)患者的临床表现、细胞遗传学和基因突变等实验室特征及预后因素。 方法:对符合2016年WHO诊断分型标准的16例CNL患者进行资料采集,随访患者并进行预后分析。利用直接测序法检测CSF3R、ASXL1、SETBP1、CALR、MPL基因突变状态,对有突变的样本进行克隆后测序鉴定,采用等位基因特异性聚合酶链反应(AS-PCR)检测JAK2 V617F突变。 结果: 16例CNL患者中位发病年龄为64(43~80)岁,男性占75%(12/16),确诊时中位HGB水平为114(81~154)g/L,中位WBC为41.20(26.05~167.70)×10(9)/L,中位PLT为238(91~394)×10(9)/L。中位骨髓纤维化水平为1(0~3)级。除1例t(1;7)(p32;q11)、1例+21克隆异常及1例14ps+外,余患者均为正常核型。16例CNL患者中,CSF3R T618I突变检出率为100%(16/16),ASXL1突变检出率为81%(13/16),SETBP1突变检出率为63%(10/16),1例患者携带CALR K385fs*47突变,所有患者均无JAK2 V617F突变及MPL突变。CNL患者中位生存期为24(95%CI 18~30)个月。初诊WBC≥50×10(9)/L者中位生存期较<50×10(9)/L者短(11个月对39个月,P=0.005)。 结论: CSF3R T618I突变是CNL的特异性突变。CNL患者中位生存期24个月,确诊时WBC≥50×10(9)/L是不良预后因素。.

Keywords: Gene, CSF3R; Karyotypes; Leukemia, neutrophilic, chronic; Prognosis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Marrow
  • Carrier Proteins
  • Female
  • Humans
  • Janus Kinase 2
  • Leukemia, Neutrophilic, Chronic*
  • Male
  • Middle Aged
  • Mutation
  • Nuclear Proteins
  • Polymerase Chain Reaction
  • Prognosis
  • Receptors, Colony-Stimulating Factor
  • Retrospective Studies

Substances

  • Carrier Proteins
  • Nuclear Proteins
  • Receptors, Colony-Stimulating Factor
  • SETBP1 protein, human
  • Janus Kinase 2

Grants and funding

基金项目:国家自然科学基金(81530008、81370611、81270585、81470297);北京协和学者创新研究团队